Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously.
The drug giant $(LLY)$ is also reducing the price of 2.5 mg and 5 mg vials of Zepbound, a treatment for diabetes or obesity, that has become highly popular with patients but has also been criticized for its high cost.
Lilly said it will lower the price of the 2.5 mg dose to $349 a month and cut the price of the 5 mg dose to $499 a month.
The company's new Zepbound Self Pay Journey Program offers the 7.5 mg and 10 mg doses at the new price with refills that come within 45 days of prior delivery.
Lilly's stock was up 0.8% premarket.
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 25, 2025 06:57 ET (11:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。